FDA clears path for Endeavor

The U.S. Food and Drug Administration on Friday approved the sale of a new drug-coated stent from Fridley-based Medtronic - a product that likely will take sales from rival Boston Scientific's nearby stent division in Maple Grove.
Called Endeavor, the product is the first new competitor in the multibillion dollar U.S. market for drug-coated stents since 2004, when the FDA approved Boston Scientific's market-leading Taxus product to compete against the Cypher stent from New Jersey-based Johnson & Johnson.

full article >> http://www.twincities.com/business/ci_8144016